Pediatric Cardiology

, 32:1023 | Cite as

Infliximab Treatment for Pediatric Refractory Kawasaki Disease

  • Laura L. Blaisdell
  • Jennifer A. Hayman
  • Adrian M. MoranEmail author
Case Report

Kawasaki disease (KD) was diagnosed for a previously healthy 11-year-old boy after he presented with 5 days of fever, bilateral nonpurulent conjunctivitis, extremity edema, maculopapular rash, and oropharyngeal changes. The review of the boy’s systems was notable for the aforementioned symptoms as well as for headache, diffuse abdominal pain, nonbloody nonbilious emesis, and loose stools for 1 day. His medical history was noncontributory. He took no medications, had no allergies, and had up-to-date immunizations. His growth and development were normal, and his social and family history was noncontributory.

At his physical examination, the boy had a temperature of 37.3°C (39.3°C at the referring hospital), a heart rate of 136 beats per minute (bpm), a blood pressure of 103/49 mm Hg, a respiratory rate of 38 breaths per minute, and an oxygen saturation of 95% on room air. He weighed 58.1 kg (95%) and was 155 cm in height (95%).

The boy’s physical examination was remarkable for bilateral...


Infliximab Left Anterior Descend Kawasaki Disease Abciximab Right Coronary Artery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW (1998) A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 81:1116–1120PubMedCrossRefGoogle Scholar
  2. 2.
    Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP (1998) Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 17:1144–1148PubMedCrossRefGoogle Scholar
  3. 3.
    Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD et al (2005) Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 146:662–667PubMedCrossRefGoogle Scholar
  4. 4.
    Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS et al (2008) Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 153:833–838PubMedCrossRefGoogle Scholar
  5. 5.
    Dominguez SR, Friedman K, Seewald R, Anderson MS, Willis L, Glode MP (2008) Kawasaki disease in a pediatric intensive care unit: a case-control study. Pediatrics 122:e786–e790PubMedCrossRefGoogle Scholar
  6. 6.
    Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C (2003) Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 24:145–148PubMedCrossRefGoogle Scholar
  7. 7.
    Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M et al (2006) Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 149:237–240PubMedCrossRefGoogle Scholar
  8. 8.
    Han RK, Silverman ED, Newman A, McCrindle BW (2000) Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 154:694–699PubMedGoogle Scholar
  9. 9.
    Harada K (1991) Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33:805–810PubMedGoogle Scholar
  10. 10.
    Hashino K, Ishii M, Iemura M, Akagi T, Kato H (2001) Retreatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 43:211–217PubMedCrossRefGoogle Scholar
  11. 11.
    Imagawa T, Mori M, Miyamae T, Ito S, Nakamura T, Yasui K et al (2004) Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 163:263–264PubMedCrossRefGoogle Scholar
  12. 12.
    Iwashima S, Seguchi M, Matubayashi T, Ohzeki T (2007) Ulinastatin therapy in Kawasaki disease. Clin Drug Invest 27:691–696CrossRefGoogle Scholar
  13. 13.
    Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y et al (1996) Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients. Circulation 94:1379–1385PubMedGoogle Scholar
  14. 14.
    Kawasaki T (1967) Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 16:178–222PubMedGoogle Scholar
  15. 15.
    Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T et al (2006) Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113:2606–2612PubMedCrossRefGoogle Scholar
  16. 16.
    Kobayashi T, Inoue Y, Tamura K, Morikawa A, Kobayashi T (2007) External validation of a scoring system to predict resistance to intravenous immunoglobulin. J Pediatr 150:e37; author reply e38PubMedCrossRefGoogle Scholar
  17. 17.
    Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS (1989) Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 2:1298–1302PubMedCrossRefGoogle Scholar
  18. 18.
    Matsubara T, Furukawa S, Yabuta K (1990) Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 56:29–36PubMedCrossRefGoogle Scholar
  19. 19.
    Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K et al (2004) Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch Dis Child 89:776–780PubMedCrossRefGoogle Scholar
  20. 20.
    Momenah T, Sanatani S, Potts J, Sandor GG, Human DG, Patterson MW (1998) Kawasaki disease in the older child. Pediatrics 102:e7PubMedCrossRefGoogle Scholar
  21. 21.
    Muta H, Ishii M, Sakaue T, Egami K, Furui J, Sugahara Y et al (2004) Older age is a risk factor for the development of cardiovascular sequelae in Kawasaki disease. Pediatrics 114:751–754PubMedCrossRefGoogle Scholar
  22. 22.
    Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T (2006) Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 95:189–193PubMedCrossRefGoogle Scholar
  23. 23.
    Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL et al (2007) Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 356:663–675PubMedCrossRefGoogle Scholar
  24. 24.
    O’Connor MJ, Saulsbury FT (2007) Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab. Clin Pediatr Phila 46:345–348PubMedCrossRefGoogle Scholar
  25. 25.
    Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A et al (2007) Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 4Google Scholar
  26. 26.
    Oishi T, Fujieda M, Shiraishi T, Ono M, Inoue K, Takahashi A et al (2008) Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ J 72:850–852PubMedCrossRefGoogle Scholar
  27. 27.
    Raman V, Kim J, Sharkey A, Chatila T (2001) Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J 20:635–637PubMedCrossRefGoogle Scholar
  28. 28.
    Saji T (2008) Clinical utility of ulinastatin, urinary protease inhibitor in acute Kawasaki disease. Nippon Rinsho 66:343–348PubMedGoogle Scholar
  29. 29.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M et al (2008) Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 27:155–160PubMedGoogle Scholar
  30. 30.
    Wallace CA, French JW, Kahn SJ, Sherry DD (2000) Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 105:E78PubMedCrossRefGoogle Scholar
  31. 31.
    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS (2004) Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31:808–810PubMedGoogle Scholar
  32. 32.
    Williams RV, Wilke VM, Tani LY, Minich LL (2002) Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 109:E4PubMedCrossRefGoogle Scholar
  33. 33.
    Wright DA, Newburger JW, Baker A, Sundel RP (1996) Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 128:146–149PubMedCrossRefGoogle Scholar
  34. 34.
    Zulian F, Zanon G, Martini G, Mescoli G, Milanesi O (2006) Efficacy of infliximab in long-lasting refractory Kawasaki disease. Clin Exp Rheumatol 24:453PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Laura L. Blaisdell
    • 1
  • Jennifer A. Hayman
    • 2
  • Adrian M. Moran
    • 3
    Email author
  1. 1.Department of PediatricsMaine Medical CenterPortlandUSA
  2. 2.Barbara Bush Children’s HospitalMaine Medical CenterPortlandUSA
  3. 3.Division of Pediatric Cardiology, Department of PediatricsMaine Medical CenterPortlandUSA

Personalised recommendations